Clinical trials
Phase 2 Dyskinesias trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
45 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 3 |
| 2001 | 2 |
| 2002 | 3 |
| 2004 | 3 |
| 2005 | 1 |
| 2007 | 4 |
| 2008 | 1 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 3 |
| 2013 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 3 |
| 2024 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 33 |
| Terminated | 8 |
| Recruiting | 1 |
| Suspended | 1 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | 10 |
| Novartis Pharmaceuticals | 6 |
| Novartis | 4 |
| Bukwang Pharmaceutical | 2 |
| University Health Network, Toronto | 2 |
| University of Colorado, Denver | 2 |
| AbbVie (prior sponsor, Abbott) | 1 |
| Addex Pharma S.A. | 1 |
| Amarantus BioScience Holdings, Inc. | 1 |
| Appello Pharmaceuticals, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dyskinesias | 45 |
| Parkinson Disease | 37 |
| Movement Disorders | 8 |
| Dyskinesia, Drug-Induced | 3 |
| Parkinsonian Disorders | 3 |
| Psychotic Disorders | 3 |
| Anxiety Disorders | 2 |
| Marijuana Abuse | 2 |
| Neurologic Manifestations | 2 |
| Tremor | 2 |
Trials
Showing 26 to 45 of 45. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.